Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand–siRNA Conjugates-Reference-Cited by-同舟云学术

Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand–siRNA Conjugates

Published:2022-01-12 Issue:2 Volume:17 Page:292-298
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Harumoto Toshimasa¹,Iwai Hiroto¹,Tanigawa Mari¹,Kubo Toshiko¹,Atsumi Toshiyuki¹,Tsutsumi Kyoko¹,Takashima Michio¹,Destito Giuseppe²,Soloff Rachel²,Tomizuka Kazuma¹,Nycholat Corwin³,Paulson James³^ORCID,Uehara Keiji¹^ORCID

Affiliation:

1. Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

2. Kyowa Kirin Inc., 9420 Athena Circle, La Jolla, California 92037, United States

3. Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Funder

Kyowa Kirin

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.1c00652

Reference30 articles.

1. Drugging the 'undruggable' cancer targets

2. RNAi Therapies: Drugging the Undruggable

3. Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

4. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

5. Comprehensive Structure–Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of glycosylated nucleosides in small synthetic glyco‐RNAs;ChemBioChem;2024-01-31

2. Development of magnetic nanoparticles with double silica shells of different porosities for efficient siRNA delivery to breast cancer cells;Materials Advances;2024

3. Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors;Molecular Pain;2024-01

4. Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors;2023-12-18

5. Synthesis of peptide–siRNA conjugates via internal sulfonylphosphoramidate modifications and evaluation of their in vitro activity;Nucleic Acids Research;2023-11-16